Real-world data is essential to understanding how therapies perform beyond clinical trials, particularly in rare diseases like Niemann-Pick disease type C (NPC). As healthcare increasingly prioritizes evidence that reflects everyday patient experience, the need for meaningful patient-reported outcomes continues to grow. In collaboration with IntraBio, Curant Rare developed a first-of-its-kind real-world evidence (RWE) system that […]
PlanPlus by Curant Health Serves Security Health Plan Heart Failure Members and Significantly Reduces Total Cost of Care in One Year. Authors: Jeremy Combs, MBA1 (Corresponding author: jcombs@curanthealth.com) John Cox, MD2 Paula Jacobson3 Executive Summary In 2023, Security Health Plan (SHP) partnered with PlanPlus by Curant Health to address rising Total Cost of Care (TCOC) among members diagnosed with Congestive Heart Failure (CHF). Heart failure is one of […]
Each year, Medicare Stars cut points continue to rise, and 2026 is no exception. Nearly 60% of all cut points increased year over year, including approximately 60% of 4-Star thresholds, further reinforcing how challenging it has become to achieve and sustain high performance. As expectations continue to climb, plans must shift from reactive adjustments to […]
Atlanta, GA – Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products. Rare disease therapies face unique challenges, including complex regulatory pathways and access barriers. This collaboration will leverage Cencora’s pharmaceutical logistics services and commercialization solutions, such as pharmacovigilance and market access support, and Curant Rare’s specialty pharmacy services and omnichannel patient engagement solutions. The integrated solution aims to streamline […]
ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate the complexities of treatment. Patients will now benefit from Curant Rare’s proven high-touch care model, designed to ensure […]
Atlanta, GA – August 18, 2025 – Curant Health is proud to announce that Curant Rare is now the exclusive pharmacy partner for IWILFIN™, a groundbreaking therapy used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB). Beginning in August 2025, patients will transition to Curant Rare with one clear […]
WICHITA, Kan.--(BUSINESS WIRE)--Curant Health, a leading national specialty pharmacy serving communities for over 25 years, officially announces the opening of its new on-site pharmacy at The University of Kansas School of Medicine-Wichita Medical Practice Association. This new location seeks to enhance patient convenience and deliver comprehensive care by seamlessly combining doctor visits with pharmacy services. […]
ATLANTA--(BUSINESS WIRE)--Curant Health, a multifaceted Medication Care Management® organization dedicated to the care of complex patients nationwide, is proud to announce the launch of its PlanPlus™ business unit. PlanPlus™ is solely focused on improving the clinical health outcomes of Health Plan member populations via award-winning complex care patient services, and unmatched business intelligence capabilities. Curant Health is URAC, […]
ATLANTA--(BUSINESS WIRE)--Curant Health, a multifaceted Medication Care Management® organization, dedicated to the care of complex patients nationwide, is proud to announce the launch of our Curant Rare™ business unit. Curant Rare™ utilizes our complex care patient services and unmatched business intelligence capabilities within our award-winning specialty pharmacy platform to improve the clinical health outcomes of patients suffering from […]
ATLANTA--(BUSINESS WIRE)--Curant Health, a rare disease specialty pharmacy that improves health outcomes for rare and complex care patients, has been chosen by IntraBio as the exclusive specialty pharmacy for AQNEURSA™ (levacetylleucine). This groundbreaking therapy is the first FDA-approved stand-alone treatment for Niemann-Pick Disease Type C (NPC), a rare genetic disorder. AQNEURSA™ represents a significant advancement in the […]
